Provention Bio (NASDAQ:PRVB – Get Rating) had its target price hoisted by SVB Leerink from $16.00 to $19.00 in a research report released on Monday, Stock Target Advisor reports. They currently have an outperform rating on the stock.
Other analysts also recently issued reports about the company. Oppenheimer lifted their price objective on Provention Bio from $14.00 to $18.00 and gave the company an outperform rating in a report on Friday. Jefferies Financial Group boosted their target price on shares of Provention Bio from $18.00 to $22.00 and gave the stock a buy rating in a report on Friday. Finally, Chardan Capital boosted their target price on shares of Provention Bio from $24.00 to $30.00 and gave the stock a buy rating in a report on Friday. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of Buy and an average target price of $21.40.
Provention Bio Stock Performance
PRVB stock opened at $7.77 on Monday. The company has a debt-to-equity ratio of 0.16, a current ratio of 7.58 and a quick ratio of 7.58. The business has a 50-day moving average price of $6.41 and a 200 day moving average price of $5.04. The company has a market capitalization of $677.47 million, a P/E ratio of -4.98 and a beta of 2.36. Provention Bio has a 1-year low of $3.18 and a 1-year high of $9.65.
Institutional Investors Weigh In On Provention Bio
About Provention Bio
Provention Bio, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease.
- Get a free copy of the StockNews.com research report on Provention Bio (PRVB)
- Three Ways To Win The Online Gambling Industry
- Santa Claus Rally? Here’s What Needs to Happen
- Will the Return of Bob Iger Return the Magic to Disney Stock?
- Is Ardelyx is A Buy After Slip in Early 2022
- Is Tesla A Bargain Now As It Trades At Two-Year Lows?
Receive News & Ratings for Provention Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provention Bio and related companies with MarketBeat.com's FREE daily email newsletter.